Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948961 · ClinicalTrials.gov registry record · Phase 1
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT00948961: Completed Phase 1 study, sponsored by Celldex Therapeutics.
NCT00948961 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 70 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00948961, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
Interventions
- BIOLOGICAL CDX-1401 in combination with Resiquimod and/or Poly-ICLC
- BIOLOGICAL CDX-1401
- BIOLOGICAL Resiquimod
- BIOLOGICAL poly-ICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
What the finished NCT00948961 record still lists
NCT00948961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 4 interventions - of which CDX-1401 in combination with Resiquimod and/or Poly-ICLC is the first listed.
NCT00948961 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00948961 about?
NCT00948961 is a clinical study titled "A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1". The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
What is the current status of trial NCT00948961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2009-09. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00948961?
The interventions under investigation include: CDX-1401 in combination with Resiquimod and/or Poly-ICLC (BIOLOGICAL), CDX-1401 (BIOLOGICAL), Resiquimod (BIOLOGICAL), poly-ICLC (BIOLOGICAL).
Who is sponsoring clinical trial NCT00948961?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00948961's enrollment target sits among peer trials
70 749th of 2000 higher than 1,227 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia